Abcodia, a London, UK-based company engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening, has raised £1m in funding.
Investors include Albion Ventures and UCL Business Plc.
The company intends to use the funds to expand the team and build long term partnerships with both commercial and academic groups to make discoveries and improve the diagnosis of major cancers – colon, lung, pancreatic – as well as other conditions such as diabetes, osteoporosis and rheumatoid arthritis leveraging its longitudinal serum biobank licensed from University College London (UCL).
Abcodia is led by CEO Julie Barnes.
FinSMEs
25/05/2011